Comprehensive Molecular Screening in a Cohort of Young Men Who Have Sex With Men and Transgender Women: Effect of Additive Rectal Specimen Source Collection and Analyte Testing.
Chlamydia Infections
/ diagnosis
Chlamydia trachomatis
/ genetics
Female
Gonorrhea
/ diagnosis
Homosexuality, Male
/ statistics & numerical data
Humans
Male
Mass Screening
/ methods
Mycoplasma Infections
/ diagnosis
Mycoplasma genitalium
/ genetics
Neisseria gonorrhoeae
/ genetics
Nucleic Acid Amplification Techniques
/ methods
Prevalence
Rectum
/ microbiology
Sexually Transmitted Diseases
/ diagnosis
Transgender Persons
/ statistics & numerical data
Trichomonas Infections
/ diagnosis
Trichomonas vaginalis
/ genetics
Urine
/ microbiology
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
This study's purposes were to characterize detection rates of several sexually transmitted infection (STI) agents and describe the effect additional specimen source and analyte screening has on STI detection within a cohort of young men who have sex with men and transgender women. Within a 16-month interval, 1966 encounters involved dual urine and rectal swab submissions assessed by commercial transcription-mediated amplification-based assays for Chlamydia trachomatis and Neisseria gonorrhoeae and by off-label transcription-mediated amplification-based Trichomonas vaginalis and Mycoplasma genitalium testing. Identification of STI carriers used algorithms involving Food and Drug Administration-cleared screening methods, laboratory-modified testing for extraurogenital C. trachomatis and N. gonorrhoeae, and laboratory-developed tests for T. vaginalis and M. genitalium. Food and Drug Administration-indicated urine C. trachomatis and N. gonorrhoeae screening revealed 39 encounters (2.0%) yielding one or both agents. Via C. trachomatis and N. gonorrhoeae screening that included rectal swab analysis, 264 encounters (13.4%) yielded evidence of either (140 C. trachomatis, 88 N. gonorrhoeae) or both (36 participants) infections. Detection rates for C. trachomatis and N. gonorrhoeae were 1.4% and 0.6% for urine screening and 8.2% and 6.2% for rectal screening, respectively. Off-label screening identified 413 additional encounters with STI (5 T. vaginalis, 396 M. genitalium, 12 with both). Of these identifications, 82.1% were generated from analysis of rectal swabs (4 participants with T. vaginalis, 323 participants with M. genitalium, 12 with both). Overall detection rates of T. vaginalis (0.2% urine, 1.3% rectal) and M. genitalium (9.1% urine, 21.5% rectal) were variable. Additive analyte testing, including extraurogenital collections, contributes to comprehensive STI screening within a high-risk demographic.
Sections du résumé
BACKGROUND
This study's purposes were to characterize detection rates of several sexually transmitted infection (STI) agents and describe the effect additional specimen source and analyte screening has on STI detection within a cohort of young men who have sex with men and transgender women.
METHODS
Within a 16-month interval, 1966 encounters involved dual urine and rectal swab submissions assessed by commercial transcription-mediated amplification-based assays for Chlamydia trachomatis and Neisseria gonorrhoeae and by off-label transcription-mediated amplification-based Trichomonas vaginalis and Mycoplasma genitalium testing. Identification of STI carriers used algorithms involving Food and Drug Administration-cleared screening methods, laboratory-modified testing for extraurogenital C. trachomatis and N. gonorrhoeae, and laboratory-developed tests for T. vaginalis and M. genitalium.
RESULTS
Food and Drug Administration-indicated urine C. trachomatis and N. gonorrhoeae screening revealed 39 encounters (2.0%) yielding one or both agents. Via C. trachomatis and N. gonorrhoeae screening that included rectal swab analysis, 264 encounters (13.4%) yielded evidence of either (140 C. trachomatis, 88 N. gonorrhoeae) or both (36 participants) infections. Detection rates for C. trachomatis and N. gonorrhoeae were 1.4% and 0.6% for urine screening and 8.2% and 6.2% for rectal screening, respectively. Off-label screening identified 413 additional encounters with STI (5 T. vaginalis, 396 M. genitalium, 12 with both). Of these identifications, 82.1% were generated from analysis of rectal swabs (4 participants with T. vaginalis, 323 participants with M. genitalium, 12 with both). Overall detection rates of T. vaginalis (0.2% urine, 1.3% rectal) and M. genitalium (9.1% urine, 21.5% rectal) were variable.
CONCLUSIONS
Additive analyte testing, including extraurogenital collections, contributes to comprehensive STI screening within a high-risk demographic.
Identifiants
pubmed: 33045163
doi: 10.1097/OLQ.0000000000001244
pii: 00007435-202011000-00006
pmc: PMC9624201
mid: NIHMS1611568
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-753Subventions
Organisme : NIDA NIH HHS
ID : U01 DA036939
Pays : United States
Organisme : NIDA NIH HHS
ID : F32 DA046313
Pays : United States
Références
AIDS Behav. 2012 May;16(4):872-81
pubmed: 21983694
J Clin Microbiol. 1998 Jan;36(1):191-7
pubmed: 9431945
Sex Transm Dis. 2008 Sep;35(9):797-800
pubmed: 18607317
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
J Clin Microbiol. 2017 Oct;55(10):2894-2902
pubmed: 28724558
J Med Microbiol. 2018 Aug;67(8):1050-1057
pubmed: 29927376
Biotechniques. 1995 Mar;18(3):418-22
pubmed: 7779390
Sex Transm Infect. 2018 Sep;94(6):406-410
pubmed: 29567802
J Clin Microbiol. 1997 Apr;35(4):995-8
pubmed: 9157172
Am J Prev Med. 2018 Aug;55(2):151-158
pubmed: 29937115
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S837-48
pubmed: 26602621
J Clin Microbiol. 2012 Jun;50(6):2005-8
pubmed: 22493338
Sex Transm Dis. 2008 Jul;35(7):637-42
pubmed: 18520976
Clin Microbiol Rev. 2010 Jul;23(3):550-76
pubmed: 20610823
Int J STD AIDS. 2018 Dec;29(14):1444-1447
pubmed: 30114993
J Clin Microbiol. 1998 Nov;36(11):3122-6
pubmed: 9774550
J Clin Microbiol. 2006 Feb;44(2):400-5
pubmed: 16455891
J Clin Microbiol. 2016 Dec 28;55(1):321-325
pubmed: 27629896
J Acquir Immune Defic Syndr. 2008 May 1;48(1):109-12
pubmed: 18209679
Am J Obstet Gynecol. 2009 Feb;200(2):188.e1-7
pubmed: 19185101
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):537-43
pubmed: 19935075
Arch Sex Behav. 2019 May;48(4):1099-1110
pubmed: 30888554
Sex Transm Infect. 2009 Jun;85(3):182-6
pubmed: 19126571
Sex Transm Infect. 2012 Jun;88(4):288-93
pubmed: 22328644
J Med Microbiol. 2005 Apr;54(Pt 4):357-360
pubmed: 15770020
J Clin Microbiol. 2013 Jan;51(1):101-4
pubmed: 23100348
Clin Infect Dis. 2018 Feb 10;66(5):796-798
pubmed: 29028993
J Clin Microbiol. 2006 Sep;44(9):3306-12
pubmed: 16954265
Sex Transm Dis. 2019 Jun;46(6):357-363
pubmed: 31095100